Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients

Buzon-Martín Luis,Montero-Baladía Miguel, Delgado-López Pedro,Iglesias-Posadilla David,Astigarraga Itziar, Galacho-Harriero Ana,Iglesias-Julián Enrique,López-Veloso María,De La Torre-Ferrera Noelia, Barraza-Bengoechea Julio César, Ubeira-Iglesias Marta, San Llorente-Sebastián Rodrigo,Colazo-Burlato María, Lorenzo-Martín Andrés,Minguito de la Iglesia Javier, García-Muñoz Juan Pablo, Hermida-Fernández Gerardo,Navarro-San Francisco Carolina, Boado-Lama Jorge, Fernández-Regueras María,Callejo-Torre Fernando, Ossa-Echeverri Sergio, Fisac-Cuadrado Lourdes, Gero-Escapa María,Megías-Lobón Gregoria, Simón-Rodríguez Adolfo, Fernández-Ratero José Antonio

Journal of Translational Autoimmunity（2021）

引用 11|浏览3

暂无评分

摘要

•Immune dysregulation and thrombotic phenomena seem to be key features in the pathophysiology of COVID-19.•Corticoids have proven effective in reducing mortality among severely ill COVID-19 patients.•The combination of corticoids and interleukin inhibitors may reduce the need for mechanical ventilation in severe cases.•Aggressive immunomodulatory therapy results in good overall outcome with acceptable infectious/thrombotic complications.

查看译文

关键词

COVID-19,Coronavirus,SARS-CoV-2,Epidemiology,Diagnosis,Treatment,Immunomodulation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要